AI-generated from publicly available materials.Orchard has introduced AudienceIQ, a cutting-edge AI tool designed to create synthetic personas for patients and clinicians, aimed at revolutionizing pharmaceutical marketing.
This innovative platform addresses a significant challenge in the pharmaceutical sector: the traditionally slow and costly nature of market research. By leveraging evidence-based personas, AudienceIQ allows marketing and medical teams to rapidly test concepts and materials, significantly reducing the time frame from months to mere days. This agility enables teams to continuously refine their strategies based on real-time insights rather than relying solely on assumptions.
AudienceIQ utilizes a foundation of published research, public datasets, and actual conversations with patients and clinicians to generate comprehensive personas across various audience segments. This functionality enables teams to analyze how different stakeholders might respond to messaging, positioning, and creative content before launching any campaigns. Moreover, clients can enhance these personas with their proprietary research, ensuring data security and exclusivity.
According to Orchard CEO Wai Kwok, the necessity for evidence-based decision-making in marketing has never been more critical. He emphasizes that the traditional approach of conducting a single annual study is outdated. With the fast-paced evolution of marketing channels and competition, AudienceIQ provides the tools needed for teams to adapt and innovate swiftly. The recent launch follows a panel discussion on AI's role in patient-centered care, highlighting the ongoing dialogue about the balance between technological advancement and genuine patient engagement.